Elevated serum amylase levels were observed in patients with acute liver failure and hepatic encephalopathy, with some cases showing concomitant pancreatitis. The exact cause linking liver failure and pancreatitis remains unclear.
Area of Science:
Gastroenterology
Hepatology
Pathology
Context:
Acute liver failure and hepatic encephalopathy are critical conditions affecting liver function.
Serum amylase is an enzyme primarily associated with pancreatic function.
The co-occurrence of elevated amylase and liver disease warrants further investigation.
Purpose:
To investigate the prevalence of elevated serum amylase in patients with acute liver failure and hepatic encephalopathy.
To determine the incidence of pancreatitis in patients with liver failure.
To explore potential pathogenetic links between liver failure and pancreatitis.
Summary:
Increased serum amylase was detected in 41% of patients with acute liver failure-induced coma and 14% with hepatic encephalopathy.
Pancreatitis was diagnosed post-mortem in 11.7% of acute liver failure patients and 7% of hepatic encephalopathy patients.
The pathogenesis of pancreatitis in liver failure is multifactorial, potentially involving viral infections, toxins, hemodynamic changes, coagulation issues, and metabolic disturbances.
Impact:
Highlights a potential association between liver dysfunction and pancreatic injury.
Suggests serum amylase may be a relevant biomarker in liver failure patients.
Underscores the need for further research into the complex interplay between liver and pancreatic diseases.